Results 41 to 50 of about 5,464 (192)

The use of abciximab associated with primary angioplasty for treating acute myocardial infarction

Arquivos Brasileiros de Cardiologia, 2002
OBJECTIVE: To assess the benefit resulting from the use of abciximab associated with primary angioplasty. The following parameters were analyzed in-hospital, at 30 days, and 6 months: (a) flow in the culprit artery; (b) ventricular function; (c) combined
Manuel Lisandro Hernández Brito, Newton F. Stadler de Souza Filho, Álvaro Vieira Moura, Luiz Augusto Lavalle, Rubens Zenobio Darwich, Marisa Leal, Eva Cantalejo Munhoz   +6 more
doaj   +1 more source

Stent Thrombosis: A Narrative Review From Pathophysiology to Therapy

Clinical Cardiology, Volume 49, Issue 4, April 2026.
Stent thrombosis remains a life‐threatening complication of PCI driven by complex interactions between stent design, procedural factors, thrombogenic milieu, and inflammation. This review integrates pathophysiological mechanisms with contemporary and emerging therapeutic strategies, highlighting optimized PCI, tailored antithrombotic therapy, and novel
Emanuele Cecchi, Andrea Grasso Granchietti, Ruggero Mazzotta, Manuel Garofalo, Giorgia Panichella, Giuseppe Iula, Francesca Maria Di Muro, Silvia Menale, Rossella Marcucci   +8 more
wiley   +1 more source

Abciximab-induced delayed profound thrombocytopaenia

, 2017
No commercial use is permitted unless otherwise expressly granted. Abciximab, the first approved glycoprotein (GP IIb/IIIa) inhibitor, is being widely used during acute coronary syndromes and offers the promising approach to antithrombotic therapy.
Kailash Bajaj, Jbara, Manar, Chhabra, Lovely, Sukhdeep Bhogal, Manar Jbara, Bhogal, Sukhdeep, Bajaj, Kailash, Lovely Chhabra   +7 more
core   +1 more source

Abciximab [PDF]

Reactions Weekly, 2021
openaire   +3 more sources

Distinct Thromboxane A₂–Dependent Pathways Regulate Arachidonic Acid–Triggered VASP Phosphorylation at Ser239 and Ser157 in Human Platelets: Real‐Time Visualization Reveals Superior Antithrombotic Efficacy by Targeting Thromboxane A₂ Signaling over Cyclooxygenase Inhibition

Journal of Cellular Physiology, Volume 241, Issue 3, March 2026.
ABSTRACT Platelets, as anucleate blood cells, play a pivotal role in the pathogenesis of cardiovascular diseases (CVDs), making antiplatelet therapy essential for preventing thrombotic events such as myocardial infarction. Thromboxane A₂ (TXA₂) is a key pro‐aggregatory mediator that drives platelet activation.
Joen‐Rong Sheu, Wei‐Chieh Huang, Chao‐Chien Chang, Chih‐Wei Hsia, Chih‐Hsuan Hsia, Thanasekaran Jayakumar, Shaw‐Min Hou   +6 more
wiley   +1 more source

TEG®6s system measures the contributions of both platelet count and platelet function to clot formation at the site-of-care

Platelets, 2020
Knowledge of platelet count and function is key to ensuring appropriate hemostatic management. We hypothesized that the novel, portable TEG®6s coagulation assessment system could evaluate the contribution of both platelet count and function to clot ...
Joao D. Dias, Carlos G Lopez-Espina, Kevin Bliden, Paul Gurbel, Jan Hartmann, Hardean E Achneck   +5 more
doaj   +1 more source

Single center experience with provisional abciximab therapy in complex lower limb interventions

, 2008
BACKGROUND: Abciximab, a glycoprotein IIb/IIIa antagonist has been shown to improve patency and clinical outcome in patients undergoing endovascular recanalization of femoro-popliteal occlusions.
Diehm, Nicolas, Keo, H, Baumgartner, Iris, Diehm, N, Baumgartner, R, Husmann, Marc, Keo, Hak Hong, Husmann, M, Baumgartner, I   +8 more
core   +1 more source

Abciximab induced severe thrombocytopenia in an elderly patient

, 2022
Abciximab is a humanized monoclonal antibody which acts against αIIbβ3 receptor. The use of abciximab with percutaneous coronary interventions (PCI) has proven good results in patients.
Sen, Aastha, Joseph, Girish, Gautam, Vinay, Bhatti, Neena   +3 more
core   +2 more sources

Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: Ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions

, 2000
Background We examined the ex vivo platelet aggregation profiles of patients who underwent percutaneous coronary intervention and received either abciximab, ticlopidine, or both agents.Study Design and Methods The trial was a prospective, nonrandomized ...
Maresh, K, Taylor, RJ, Kleiman, NS, Mascelli, MA, Frederick, B, Grazeiadei, N, Lance, ET, Effron, MB, Jordan, RE   +8 more
core   +1 more source

Self-Reporting Theranostic: Nano Tool for Arterial Thrombosis

Bioengineering, 2023
Arterial thrombosis (AT) originates through platelet-mediated thrombus formation in the blood vessel and can lead to heart attack, stroke, and peripheral vascular diseases.
Suryyani Deb, Mohammad Azharuddin, Sofia Ramström, Kanjaksha Ghosh, Santiswarup Singha, Thobias Romu, Hirak Kumar Patra   +6 more
doaj   +1 more source